杨贵妃传媒視頻

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 杨贵妃传媒視頻 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Oct 4 2022

Full Issue

No Child Developmental Harm From Antidepressants In Pregnancy: Study

Risk of autism, ADHD, behavioral disorders, and other issues in children up to age 14 are not related to the taking of antidepressants during pregnancy, according to new data. Separately, reports cover scientists researching why CAR-T therapies work against only some cancers.

Antidepressant use during pregnancy was not associated with autism, attention-deficit hyperactivity disorder (ADHD), behavioral disorders, developmental speech, language, learning and coordination disorders or intellectual disabilities, according to a study of over 145,000 women and their children across the United States followed for up to 14 years. (LaMotte, 10/4)

In other pharmaceutical research 鈥

When CAR-T therapy works against blood cancer, it can work spectacularly, but cancer still returns for many patients. In lymphoma, scientists are just beginning to work out why over half of treated patients don鈥檛 experience lasting remission, depending on the product. (Chen, 10/4)

Amid heightened debate over a regulatory program for speeding the approval of some medicines, a new government analysis finds extensive delays in the clinical trials that drug makers are required to conduct after approvals. (Silverman, 10/3)

More pharmaceutical industry news 鈥

The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc. (Brittain, 10/3)

The U.S. Supreme Court on Monday asked President Joe Biden's administration for its opinion on whether the court should hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award for GlaxoSmithKline LLC in a patent dispute over generic heart medication. (Brittain, 10/3)

Theranos Inc. founder Elizabeth Holmes is due back in court this month to make the case that she deserves a new trial based on her allegations that the government manipulated testimony from a key witness who testified against her. The hearing was granted Monday by the judge who presided over Ms. Holmes鈥檚 monthslong criminal-fraud trial. (Somerville, 10/3)

Kroger is threatening to exit Express Scripts' network if the pharmacy benefit manager does not agree to a more 鈥渆quitable and fair鈥 contract.聽Kroger said it has attempted--to no avail--to negotiate more favorable rates with Cigna subsidiary Express Scripts dozens of times over the past eight months, the company said in a news release. Express Scripts鈥 proposal is 鈥渇ar out of line鈥 with the industry standard, according to the supermarket company. (Tepper, 10/3)

Bluebird Bio is about to become the seller of the two most expensive drugs in the U.S., and by extension the world, each fetching nearly $3 million. While the high price tag is already leading to public backlash, one would think the company and its investors would at least see a huge payoff as the drugs finally hit the market. Not quite. Two approvals by the Food and Drug Administration this past summer might have rescued the company from the financial abyss, but the Boston-area-based Bluebird, which in April announced significant cost cuts to stay afloat, is going to be cash-strapped for a while. (Wainer, 10/3)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, June 1
  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
  • Friday, May 22
More Morning Briefings
RSS Feeds
  • 杨贵妃传媒視頻
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF